A phase 3 trial evaluating sotatercept-csrk (Winrevairâ„¢) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...
The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.
The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...
John Obaro, group managing director (GMD) of SystemSpecs, says the company remains dedicated to developing technology solutions for businesses and governments.
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in previous studies, the drugmaker said on Thursday.
All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.
This year, one of the best watches unveiled at the show was a new Zenith Chronomaster Sport model. That was one of a pair of ...
A Federal High Court on Wednesday set aside its Mareva orders that froze $225.8 million in assets and accounts linked ...
In today's episode of Fratello Talks, the guys discuss this year's LVMH Watch Week ✓ Tune in to hear about all the new releases! ✓ ...
The other injunctive orders, namely orders 6,7,8,9,10 and 11 were not discharged or set aside, and remain valid and subsisting, the counsel said.
Over two days of schmoozing with executives employed by one of the most powerful groups in the industry, here are the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback